1. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
- Author
-
Ellen L. Goode, Diether Lambrechts, Usha Menon, Sharon E. Johnatty, Kathryn L. Terry, Kelly M. Bakulski, Mary Anne Rossing, Simon A. Gayther, Gillian E. Hanley, Dale W. Garsed, Katharine Brieger, Harvey A. Risch, Celeste Leigh Pearce, Daniel W. Cramer, Susan J. Ramus, Kathleen R. Cho, Allan Jensen, Karen McLean, Anna deFazio, Holly R. Harris, Francesmary Modugno, Anna H. Wu, Paul D.P. Pharoah, Andrew Berchuck, Aleksandra Gentry-Maharaj, Susanne K. Kjaer, Britton Trabert, David D.L. Bowtell, Renée T. Fortner, Bhramar Mukherjee, Estrid Høgdall, Alice W. Lee, Aliya Alimujiang, Elisa V. Bandera, David G. Huntsman, Malcolm C. Pike, Michael S. Anglesio, Georgia Chenevix-Trench, Hoda Anton-Culver, Kirsten B. Moysich, Roberta B. Ness, Jolanta Kupryjanczyk, Nicolas Wentzensen, Susan J. Jordan, Jean L. Richardson, Hui Shen, Jennifer A. Doherty, Argyrios Ziogas, Penelope M. Webb, Marc T. Goodman, and Siri Peterson
- Subjects
0301 basic medicine ,Oncology ,PROGNOSIS ,Neoplasm, Residual ,IMPACT ,medicine.medical_treatment ,DISEASE ,0302 clinical medicine ,Ovarian carcinoma ,RISK ,Ovarian Neoplasms ,Estrogen Replacement Therapy ,Hazard ratio ,Obstetrics & Gynecology ,WOMEN ,Obstetrics and Gynecology ,Hormone replacement therapy (menopause) ,Middle Aged ,Debulking ,Progression-Free Survival ,Postmenopause ,Survival Rate ,030220 oncology & carcinogenesis ,Female ,Life Sciences & Biomedicine ,medicine.medical_specialty ,CARCINOMA ,Hormone Replacement Therapy ,ESTROGENS ,Article ,REPLACEMENT THERAPY ,03 medical and health sciences ,AGE ,Internal medicine ,medicine ,Humans ,Survival rate ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Science & Technology ,Proportional hazards model ,business.industry ,medicine.disease ,030104 developmental biology ,Hormone therapy ,Progestins ,Ovarian cancer ,business - Abstract
PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery. RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend
- Published
- 2020
- Full Text
- View/download PDF